Adjuvant radiotherapy and regional lymph node field control in melanoma patients after lymphadenectomy: Results of an intergroup randomized trial (ANZMTG 01.02/TROG 02.01)

Henderson, Melissa A.; Burmeister, Bryan; Thompson, John F.; Iulio, Juliana Di; Fisher, Richard; Hong, Agnes; Scolyer, Richard A.; Shannon, Kerwin F.; Hoesktra, H.; Ainslie, Jill

doi:10.1200/jco.2009.27.18s.lba9084

Cited by 18 publications

(20 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In five of the studies, patients with cervical, axillary as well as inguinal lymph node metastases [336,337,339,346,347] were included. Only three of these cohort studies subsequently differentiated between lymph node regions in their evaluation.…”

Section: Level Of Evidence 2bmentioning

confidence: 99%

“…With respect to the cervical region only, Strojan et al reported recurrence rates of 65 % in patients with 3 or more lymph node metastases and of 17 % in patients with 2 or fewer lymph node metastases [345]. In a prospective controlled trial by von Henderson et al, lymph node metastases of 3 cm (cervical, axillary) respectively 4 cm (inguinal) in size were defined as risk factors [347].…”

Section: Level Of Evidence 2bmentioning

confidence: 99%

See 1 more Smart Citation

Malignant Melanoma S3‐Guideline “Diagnosis, Therapy and Follow‐up of Melanoma”

Pflugfelder

Kochs

Blum

et al. 2013

J Deutsche Derma Gesell

181

148

View full text Add to dashboard Cite

Section: Level Of Evidence 2bmentioning

confidence: 99%

Section: Level Of Evidence 2bmentioning

confidence: 99%

Malignant Melanoma S3‐Guideline “Diagnosis, Therapy and Follow‐up of Melanoma”

Pflugfelder

Kochs

Blum

et al. 2013

J Deutsche Derma Gesell

181

148

View full text Add to dashboard Cite

“…Adjuvant radiation therapy has been demonstrated in a Phase III trial to reduce regional nodal recurrence and improve disease-free survival when administered to patients judged to be at high risk for regional failure on the basis of resected nodal size, number of involved nodes, and presence of extracapsular spread. The clinical tradeoff is the acute radiation dermatitis that is generally shortlived but the more significant 15-25% risk of extremity lymphedema that results from the radiation fibrosis superimposed on surgical lymphatic extirpation [15]. Ipilimumab is a recombinant human IgG1 monoclonal antibody, which binds to cytotoxic T-lymphocyte associated antigen 4 (CTLA-1) blocking its pathway; this results in T-cell potentiation, which may augment the body's immunological attack against melanoma [16].…”

Section: Discussionmentioning

confidence: 99%

Preventative and Personalized Approach to the Treatment of Malignant Melanoma: A Case Report.

Hughes

Eapen²,

Beecker³

2016

UOJM

View full text Add to dashboard Cite

P a g e 4 9 | U O J M V o l u m e 6 I s s u e 1 | M a y 2 0 1 6 Cette étude de cas porte sur le mélanome malin, un cancer de la peau potentiellement mortel avec une gestion unique. Dans le cas de notre patient, le mélanome s'est présenté 28 ans avant la présentation d'une lymphadénopathie axillaire, ce qui a été démontré par la suite comme une zone étant métastatique du mélanome. Des nodules ont été découverts dans sa rate. Suite à la fin des traitements et des suivis de routine, des nodules additionnels ont été découverts dans sa poitrine. Des préventions primaires et secondaires sont importantes pour la gestion de ce patient ainsi qu'un traitement personnalisé.C a s e Re p o r t

show abstract

“…In a randomized study with 227 patients, considered as having a high risk of recurrence, 109 were included in the adjuvant radiotherapy group and 108 were considered control. After a mean followup of 27 months, 20 patients had recurrences in the radiotherapy group and 34 in the control ( = 0.0410), indicating a better control of the local recurrences with radiotherapy but not affecting the survival rate [69].…”

Section: Adjuvant Radiotherapymentioning

confidence: 95%

Adjuvant Treatment of Melanoma

Nogueira¹,

Valero²,

Moreno³

2011

Current Management of Malignant Melanoma

View full text Add to dashboard Cite

Melanomas represent 4% of all malignant tumors of the skin, yet account for 80% of deaths from skin cancer.While in the early stages patients can be successfully treated with surgical resection, metastatic melanoma prognosis is dismal. Several oncogenes have been identified in melanoma as BRAF, NRAS, c-Kit, and GNA11 GNAQ, each capable of activating MAPK pathway that increases cell proliferation and promotes angiogenesis, although NRAS and c-Kit also activate PI3 kinase pathway, including being more commonly BRAF activated oncogene. The treatment of choice for localised primary cutaneous melanoma is surgery plus lymphadenectomy if regional lymph nodes are involved. The justification for treatment in addition to surgery is based on the poor prognosis for high risk melanomas with a relapse index of 50-80%. Patients included in the high risk group should be assessed for adjuvant treatment with high doses of Interferon-2b, as it is the only treatment shown to significantly improve disease free and possibly global survival. In the future we will have to analyze all these therapeutic possibilities on specific targets, probably associated with chemotherapy and/or interferon in the adjuvant treatment, if we want to change the natural history of melanomas.

show abstract

Adjuvant radiotherapy and regional lymph node field control in melanoma patients after lymphadenectomy: Results of an intergroup randomized trial (ANZMTG 01.02/TROG 02.01)

Cited by 18 publications

References 0 publications

Malignant Melanoma S3‐Guideline “Diagnosis, Therapy and Follow‐up of Melanoma”

Malignant Melanoma S3‐Guideline “Diagnosis, Therapy and Follow‐up of Melanoma”

Preventative and Personalized Approach to the Treatment of Malignant Melanoma: A Case Report.

Adjuvant Treatment of Melanoma

Contact Info

Product

Resources

About